Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

Executive Summary

With tensions rising in the first-line NSCLC space, AstraZeneca's update on the analysis plan of its Phase III MYSTIC trial has analysts reassessing the firm’s chances against stiff competition.


Related Content

Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study
Merck Stretches Lead As EU Approves Keytruda In First-Line NSCLC
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
The New World Of Pharma – Markets, Messaging And The Flash Mob
Bristol, AstraZeneca Changes To IO Strategy Could Ultimately Be Regulatory Gain
Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
Game Changer: Merck's Stealth Keytruda-Chemo Filing Stirs NSCLC Market Dynamics
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst